Via β-catenin activation, TGF-β impairs T cell mediated immune surveillance and subsides DC recruitment to the tumor site, consequently incurring HCC immune escape and resistance to anti-PD1 treatment (Ruiz de Galarreta et al., 2019). Here, PDCD1 is linked to neoplasm.